OKYO OKYO Pharma Ltd IFRS Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1849296
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-03-31 | FY2024*2024-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $2.25M | $8.24M |
| Interest expense | $878,174 | $1.05M |
| Pretax income | -$7.97M | -$16.80M |
| Income tax | $3.26M | -$22,416 |
| Net income | -$4.71M | -$16.83M |
| EPS (basic) | -0.20 | -0.57 |
| EPS (diluted) | -0.20 | -0.57 |
| Balance sheet | ||
| Cash & equivalents | $1.56M | $826,848 |
| Current assets | $3.68M | $1.54M |
| PP&E, netmay include right-of-use assets (IFRS) | $2,035 | $3,350 |
| Total assets | $3.68M | $1.54M |
| Current liabilities | $9.23M | $7.42M |
| Short-term debt | $2.70M | — |
| Total liabilities | $9.23M | $7.42M |
| Shareholders' equity | -$5.55M | -$5.88M |
| Cash flow statement | ||
| Operating cash flow | -$1.81M | -$9.49M |
| Capital expenditure | $1,208 | — |
| Free cash flow | -$1.81M | — |
| Investing cash flow | -$1,208 | — |
| Financing cash flow | $2.66M | $6.21M |
| Depreciation & amortization | $2,563 | $3,866 |
| Stock-based compensation | $734,989 | $1.12M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.